Announcement of Glyxambi launch popularizes Jardiance & Trajenta

As it was recently known a Boehringer Ingelheim diabetes treatment combined by DPP-4 and SGLT-2 inhibitors, ‘Glyxambi’ applied for commercialization approval from the Ministry of Food and Drug Safety(MFDS), ‘Trajenta(generic name: linagliptin)’ and ‘Jardiance(generic name: empagliflozin)’ have attracted attention of the industry.  

Trajenta is a best seller competing for the 1^st and 2^nd sales ...